STOCK TITAN

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) will report financial results for Q4 and full year 2023 on March 28, 2024, showcasing its CellFX Nanosecond Pulsed Field Ablation™ technology. Investors can join the conference call or watch the webcast.
Positive
  • None.
Negative
  • None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

FAQ

When will Pulse Biosciences report financial results for Q4 and full year 2023?

Pulse Biosciences will report financial results for Q4 and full year 2023 on March 28, 2024.

What technology does Pulse Biosciences leverage?

Pulse Biosciences leverages its CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology.

How can investors listen to the conference call?

Investors can listen to the conference call by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers.

Where can the webcast of the event be accessed?

The live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

Pulse Biosciences, Inc

NASDAQ:PLSE

PLSE Rankings

PLSE Latest News

PLSE Stock Data

1.00B
17.26M
71.93%
9.32%
4.12%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
HAYWARD